- RESEARCH HIGHLIGHT
Chimeric antigen receptor (CAR)-T cell therapies have transformed the treatment of B cell malignancies, offering durable responses. However, their broader application is hampered by complex and costly manufacturing, the need for lymphodepleting chemotherapy, and the risks associated with integrating vectors. These challenges pose substantial barriers to access, especially in autoimmune diseases and newly diagnosed cancer patients, where the affected population is large and both short and long-term safety are critical.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41573-025-00134-7
